• 의료법학
• /
• 제15권1호
• /
• pp.211-237
• /
• 2014

Because of unpredictability and high possibility of abnormal results by clinical trials compared to general medical behaviors, a procedure for ensuring with sufficient explanations by investigators must be secured. Therefore, in a sequence of clinical trials, what kinds of scope, stage, and method of explanations provided by investigators, including doctors or researchers, to trial subjects are closely related to the compensation for damages by violation of liability for explanation. In case of application of clinical trials to patients who have critical illness such as cancer, issues of "Quality of Life" regarding trial subjects, cancer patients, should be discussed. Especially, in case of clinical trials for terminal cancer patients, the right of subjects' self-determination, which is a fundamental principle in medical behaviors, should be discussed. The right of self-determination includes participation in clinical trials for the possibility of life-sustaining even a little bit, or no participation in clinical trials in order to have a time for completing the rest of his life. Like this, if the extent and scope of explanations related to the issues of "Quality of Life" are raised as main issues, the evaluation of "Quality of Life", should be a prerequisite. In many occasions, realistically, despite bad results such as deaths or serious adverse drug reactions after clinical trials, it may not be easy for compensating to trial subjects or their survivors, who requested civil compensation for damage. Futhermore, in abnormal results after concealment of clinical trials or performance of clinical trials without permission, and in the case of trial subjects' failures of proving proximate cause between the clinical trials and abnormal results, problematic results such as no protection to the trial subjects could be occurred. In performing clinical trials, investigators should provide sufficient explanations for trial subjects and secure voluntary informed consents from the trial subjects. Therefore, clinical trials without trial subjects' permissions and the informed consent process violate trial subjects' rights of self-determination, and the investigators shall be liable for compensation for damages. Then, issues might be addressed are what are essential contents of patients' "rights of self-determination" infringed by clinical trials without subjects' permissions. Two perspectives about patients' rights of self-determination might be considered. One perspective regards physical distress of patients (subjects) from therapies without sufficient explanations as the crux of the matter. The other perspective regards infringement of human dignity caused by being subjects without permission as the crux of the matter irrespective of risks' big and small influences. This research follows perspective of the latter. Forming constant fiduciary relation between investigators (doctors) and subjects (patients) pursuant medical contracts, and in accordance with this fiduciary relation, subjects, who are patients, have expectations of explanations and treatments by the best ways. If doctors and patients set this forth as a premise, doctors should assume civil liability when doctors infringe patients' expectations.

• Journal of Hospice and Palliative Care
• /
• 제20권4호
• /
• pp.235-241
• /
• 2017

목적: Palliative Performance Scale (PPS)는 진행성 암환자에서 널리 사용되는 예후도구이다. PPS 측정이 생존에 대한 예측을 의미하지만, 연속적인 PPS 측정에 대한 유용성은 추가적인 연구가 필요하다. 본 연구에서는 완화 병동에 입원한 진행성 암환자를 대상으로 PPS score의 변화와 생존간의 연관성에 대해 진행한 연구이다. 방법: 2010년 1월부터 2012년 12월까지 서울성모병원 완화의학과에 입원한 환자 606에 대한 의무기록을 통하여 입원 당일의 PPS score와 입원 3일째의 PPS score 그리고, 두 score의 차이를 측정하여 점수의 변화와 생존간의 관련성을 분석하였다. 결과: PPS score의 변화와 생존과는 통계적으로 유의한 관련이 있었다. PPS score의 변화가 30% 이하인 군과 비교하였을 때, 30% 초과된 군에서 hazard ratio가 2.66(95% CI 2.19~3.22)로 확인되었다. 입원 3일째 PPS score가 30% 이하인 경우 독립적으로 생존에 대한 예측이 가능하였으며, PPS score 30% 초과된 군과 비교했을 때 hazard ratio는 1.67 (95% CI 1.38~2.02)로 확인되었다. 입원 당시의 PPS score는 생존과 독립적인 관련성은 없었다. 결론: 후향적으로 의무기록 분석을 통해 이루어진 본 연구에서 30% 이상의 PPS score 변화는 입원중인 말기 암환자의 생존과의 관련이 확인되었다. 입원 당시의 PPS score는 생존을 예측하지 못했다. PPS score의 변화는 말기암환자에서 단일 PPS score 측정보다 더 민감한 지표일 수 있다. 차후 더 많은 환자들에서 이에 대한 다기관, 전향적 연구가 필요하다.

• Journal of Hospice and Palliative Care
• /
• 제6권1호
• /
• pp.34-44
• /
• 2003

목적 : 본 연구는 호스피스 간호가 말기암환자의 통증정도에 미치는 효과를 파악하고 분석함으로써, 말기암환자의 안위를 도모하여 전인적이고 개별화된 간호를 제공하는데 도움을 주기 위하여 시도된 단일군 전후설계(one group pre-post test)이다. 방법 : 2000년 7월부터 11월까지 전주시에 소재하는 1개 종합병원의 호스피스에 의뢰되어 연구참여에 동의한 말기암환자 37명을 대상으로 하였다. 호스피스 간호는 1주일에 $5{\sim}6$회를 조주 동안 제공하였으며, 자료분석은 실수, 백분율, 평균, 표준편차 등의 서술통계와 paired t-test로 분석하였다. 결과 : 1) 통증정도의 중증도는 통증정도가 24시간 동안 가장 심했을 때 통증점수는 중재전이 6.35점, 중재후가 4.76점이었다. 통증으로 인한 지장정도는 중재전에는 인생을 즐김(8.22점), 통상적인 일(7.46점), 보행(7.08점), 일반적인 활동(7.08점)순이었으며, 중재후에는 인생을 즐김(6.62점), 통상적인 일(6.43점), 보행(6.11점), 일반적인 활동(5.78점)순으로 중재전과 후가 동일한 순위를 보였다. 2) 통증의 중증도는 중재전보다 중재후에서 각각 유의하게 감소하였다. 영역별로 분석하였을 때 24시간 동안 가장 심했을 때 통증(t=4.085, P=0.000), 24시간 동안 가장 약했을 때 통증(t=4.020, P=0.000), 평균통증(t=4.254, P=0.000), 조사당시 바로 지금 느끼는 통증(t=5.017, P=0.000)영역에서 중재후 통증이 중재전보다 유의하게 감소하였다. 3) 통증으로 인한 지장정도는 중재전보다 중재후에서 각각 유의하게 감소하였다. 영역별로 분석하였을 때 일반적인 활동(t=3.137, P=0.003), 기분(t=6.713, P=0.000), 보행능력(t=2.027, P=0.050), 통상적인 일(t=20.132, P=0.040), 대인관계(t=4.143, P=0.000), 수면(t=4.071, P=0.000), 인생을 즐김(t=3.881, P=0.000)에서 통계적으로 유의한 차이가 나타났다. 결론 : 호스피스 간호를 제공받은 말기암환자는 제공받지 않은 말기암환자에 비해 통증정도와 삶의 치장 정도에서 모두 낮아짐이 확인되었으며, 유의한 차이를 보였다. 이상과 같이 말기암환자에 대한 호스피스 간호는 통증감소와 통증이 생활에 지장을 주는 정도를 감소하는데 효과적인 것으로 확인되었으므로 앞으로 말기암환자를 위해 적극적인 활용을 권장한다.

• Journal of Hospice and Palliative Care
• /
• 제13권2호
• /
• pp.69-75
• /
• 2010

Hospice is defined by the National Hospice and Palliative Care Organization (NHPCO, USA) and WHO, as a program of care that provides comprehensive medical, nursing and support services to dying patients and their family. Despite its broad definition, however, hospice care in Korea has been focused mostly on terminal cancer patients. Thus hospice eligibility for patients with advanced cancer is relatively easier to predict than those with other fatal chronic illnesses such as heart, lung, renal or liver diseases, and dementia. This makes it more difficult for patients and families to prepare for death and gain full benefits of hospice care. This article introduces the medical guidelines for selected non-cancer patients who are expected to live for only six months, this making it possible for patients, who are nearing the end of life, to avoid unwarranted suffering.

• Bulletin of the Korean Chemical Society
• /
• 제34권8호
• /
• pp.2480-2486
• /
• 2013

A new series of diarylamides and diarylureas having 2,3-dihydropyrrolo[3,2-b]quinoline scaffold was synthesized. Their in vitro antiproliferative activities were tested over NCI-60 cancer cell lines of nine different cancer types. Some target compounds showed good inhibition percentages over different cell lines. Among all the target compounds, compound 1f possessing 6,7-dimethoxy-2,3-dihydropyrrolo[3,2-b]quinoline nucleus, amide linker, and 4-chloro-3-(trifluoromethyl)phenyl terminal ring showed high selectivity against MCF7 and MDA-MB-468 breast cancer cell lines more than the other tested cell lines. Its inhibition percentages at $10{\mu}M$ concentration over those two cell lines were 84.97% and 87.13%, respectively.

• BMB Reports
• /
• 제33권2호
• /
• pp.184-187
• /
• 2000

Prostaglandin $E_2$ ($PGE_2$) plays an important role in the regulation of various gastric functions, and the growth-inhibitory activities on tumor cells are studied in vitro and in vivo. Although the mechanisms have attracted many researchers in the past decade, the molecular mechanisms of cell cycle arrest, or induction of apoptosis by $PGE_2$, is unclear. We investigated the effects of $PGE_2$ on the growth of the human gastric carcinoma cell line SNU1 and genes that are regulated by $PGE_2$ and isolated them using differential display RT-PCR (DD RT-PCR). FACS analysis suggested that SNU1 cells were arrested at the G1 phase by $PGE_2$ treatment. This growth inhibitory effect was in a time- and dose-dependent manner. Treatment of SNU1 cells with $10\;{\mu}g/ml$ $PGE_2$, followed by DD RT-PCR analysis, revealed differently expressed bands patterns from the control. Among the differently expressed clones, we found an unidentified cDNA clone (HGP-27) overexpressed in $PGE_2$-treated cells. The full-length cDNA of HGP-27 was isolated using RACE, which consisted of a 30-nt 5'-noncoding region, a 891-nt ORF encoding the 296 amino acid protein, and a 738-nt 3'-noncoding region including a poly(a) signal. This gene was localized on the short arm of chromosome number 11. Using the Motif Finder program, a myb-DNA binding repeat signature was detected on the ORF region. The COOH-terminal half was shown to have similarity with the $NH_3$-terminal domain of thioredoxin (Trx). This relation between HGP-27 and Trx implied a potential role for HGP-27 in modulating the DNA binding function of a transcription factor, myb.

• Asian Pacific Journal of Cancer Prevention
• /
• 제17권2호
• /
• pp.691-695
• /
• 2016

Protein glycosylation is the most common posttranslational modification in mammalian cells. Aberrant protein glycosylation has been reported in various diseases, including cancer. We identified and quantified the glycan structures of O-linked glycoprotein from cholangiocarcinoma (CCA) cell lines from different histological types and compared their profiles by nanospray ionization-linear ion trap mass spectrometry (NSI-$MS^n$). Five human CCA cell lines, K100, M055, M139, M213 and M214 were characterized. The results showed that the O-linked glycans of the CCA cell lines comprised tri- to hexa-saccharides with terminal galactose and sialic acids: NeuAc1Gal1GalNAc1, Gal2GlcNAc1GalNAc1, NeuAc2Gal1GalNAc1 NeuAc1Gal2GlcNAc1GalNAc1 and NeuAc2Gal2GlcNAc1GalNAc1 All five CCA cell lines showed a similar glycan pattern, but with differences in their quantities. NeuAc1Gal1GalNAc1 proved to be the most abundant structure in poorly differentiated adenocarcinoma (K100; 57.1%), moderately differentiated adenocarcinoma (M055; 42.6%) and squamous cell carcinoma (M139; 43.0%), while moderately to poorly differentiated adenocarcinoma (M214; 40.1%) and adenosquamous cell carcinoma (M213; 34.7%) appeared dominated by $NeuA_{c2}Gal_1GalNA_{c1}$. These results demonstrate differential expression of the O-linked glycans in the different histological types of CCA. All five CCA cell lines have abundant terminal sialic acid (NeuAc) O-linked glycans, suggesting an important role for sialic acid in cancer cells. Our structural analyses of glycans may provide important information regarding physiology of disease-related glycoproteins in CCA.

• Current Optics and Photonics
• /
• 제3권2호
• /
• pp.150-153
• /
• 2019

Larynx cancer is a potentially terminal and severe type of neck and head cancer in which malignant cells start to grow and spread upwards in the larynx, or voice box. Smoking tobacco, drinking hot beverages and drinking alcohol are the main risk factors for these tumors. In this study, we aimed to develop a precise, accurate and rapid chemometrics assisted Raman spectroscopy method for diagnosis of larynx cancer in deparaffinized tissue samples. In the proposed method, samples were deparaffinized and 20 microns of each tissue were located on a coverslip. Both healthy (n = 13) and cancerous tissues (n = 13) were exposed to a Raman laser (785 nm) and excitations were recorded between wavenumbers of $50{\sim}1500cm^{-1}$. An Orthogonal Partial Least Square algorithm was applied to evaluate the Raman spectrum obtained. Sensitivity and specificity of the proposed method is high enough with the aid of Principal Component Analysis (PCA) to test the whole model. Healthy and cancerous tissues were accurately and precisely clustered. A rapid, easy and precise diagnosis algorithm was developed for larynx cancer. By this method, some useful data about differences in biomolecules of each group (phospholipids, amides, tyrosine, phenylalanine collagen etc.) was also obtained from the spectra. It is claimed that the optimized method has a great potential for clustering and separating tumor tissues from healthy ones. This novel, rapid, precise and objective diagnosis method may be an alternative for the conventional methods in literature for diagnosis of larynx cancer.

• 통합자연과학논문집
• /
• 제15권4호
• /
• pp.145-152
• /
• 2022

Colon rectal cancer is one of the frequently diagnosed cancers worldwide. In recent times the drug discovery for colon cancer is challenging because of their speedy metastasis and morality of these patients. C-jun N-terminal kinase signaling pathway controls the cell cycle survival and apoptosis. Evidence has shown that JNK1 promotes the tumor progression in various types of cancers like colon cancer, breast cancer and lung cancer. Recent study has shown that inhibiting, JNK1 pathway is identified as one of the important cascades in drug discovery. One of the recent approaches in the field of drug discovery is drug repurposing. In drug repurposing approach we have virtually screened ChEMBL dataset against JNK1 protein and their interactions have been studied through Molecular docking. Cross docking was performed with the top compounds to be more specific with JNK1 comparing the affinity with JNK2 and JNK3.The drugs which exhibited higher binding were subjected to Conceptual - Density functional theory. The results showed mainly Entrectinib and Exatecan showed better binding to the target.

• 생명과학회지
• /
• 제27권10호
• /
• pp.1215-1224
• /
• 2017

현재까지 다양한 암의 발병 원인이 밝혀졌는데, 그 중 하나로써 DNA에 돌연변이가 축적되어 유전체가 불안정 해짐에 따라 암이 발생될 수 있는 기작들이 주목받고 있다. 생물정보학과 유전체학의 발달에 따라 질병 연구에 있어서 보다 더 정확하고 신뢰성 있는 바이오마커를 찾는 것이 가능해졌다. 따라서, 생물정보학과 유전체학의 연구 기반을 바탕으로 한 암의 바이오마커는 암의 조기진단뿐만 아니라, 더 나아가 암 발생 예측과 암환자의 예후 진단에 적용될 수 있다. 최근 들어 인간 유전체에서 약 45%를 차지하는 이동성 유전인자(transposable elements, TEs)가 유전자의 발현 조절과 DNA의 돌연변이를 유도함으로써 다양한 질병에 영향을 미친다는 사실이 밝혀짐에 따라, 이러한 이동성 유전인자들이 암의 발생과 어떤 연관이 있는지에 대한 연구 또한 활발히 진행되고 있다. 따라서 우리는 이동성 유전인자가 대장암과 어떤 연관성이 있는지에 대해 조사를 하였으며, 이를 어떻게 바이오마커로 활용할 수 있는지 알아보았다. 우선, 이동성 유전인자 중 인간 유전체에 많이 존재하면서 유전체에 많은 영향을 미치는 LINE-1 (long interspersed nuclear element-1, L1)과 Alu, LTR (long terminal repeat) 위주로 확인하였다. 흥미롭게도, 대장암 세포에서 LINE-1의 저메틸화, APC 유전자 내에 LINE-1 삽입, Alu의 저메틸화와 과메틸화, LTR 삽입에 따른 isoform 발생 등이 특징적으로 나타나는 것을 알 수 있었다. 또한 원발암유전자에서의 L1 저메틸화가 대장암 전이의 바이오마커로 쓰일 수 있다는 것과 Alu에 의한 MLH1 돌연변이가 가족성 및 유전성 대장암에서 흔히 발견된다는 것을 알 수 있었다. 이 때 이동성 유전인자에 의하여 영향 받는 유전자들의 발현을 in silico 발현 분석을 통하여 분석하였으며, 조직별, 성별 특이적 발현 양상을 제시하였다. 이들을 토대로 대장암 바이오마커를 개발하여 유전성 대장암의 예측 및 대장암 진단 또는 대장암 예후 예측을 통한 개인 맞춤형 치료에 활용할 수 있을 것으로 예상된다.